A Phase 1b Dose Escalation Study Evaluating the Safety and Pharmacokinetics of Venetoclax in Combination With Azacitidine in Subjects With Treatment-Naive Higher-Risk Myelodysplastic Syndromes (MDS)
Latest Information Update: 16 Jul 2024
At a glance
- Drugs Azacitidine (Primary) ; Azacitidine (Primary) ; Venetoclax (Primary)
- Indications Chronic myelomonocytic leukaemia; Myelodysplastic syndromes
- Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
- Sponsors AbbVie
- 14 Jun 2024 Planned End Date changed from 28 Jun 2024 to 8 Jan 2027.
- 14 Jun 2024 Planned primary completion date changed from 28 Jun 2024 to 8 Jan 2027.
- 12 Dec 2023 Results ( data cutoff of May 31, 2023, n=107 ) assessing Efficacy and Safety of Venetoclax in Combination with Azacitidine for the Treatment of Patients with Myelodysplastic Syndromes presented at the 65th American Society of Hematology Annual Meeting and Exposition